The invention relates to an immunogenic fusion protein which includes, at least at the C-terminal end, a first peptide which is made up of the S protein from which the transmembrane domain at the N-terminal end of a hepatitis B virus (HBV) isolate has been deleted, and, at the N-terminal end, a second peptide which is made up of the transmembrane domain and of the ectodomain of at least one envelope protein from a hepatitis C virus (HCV) isolate. The aim of the invention is also a hybrid nucleic acid molecule which codes for said fusion protein, as well as a vector comprising said hybrid nucleic acid molecule, a subviral particle comprising said fusion protein, an immunogenic composition comprising at least said fusion protein, or at least said hybrid nucleic acid molecule, or at least said subviral particle, and a cell strain for the production of said fusion protein, or of said hybrid nucleic acid molecule, or of said subviral particle.本發明係關於一種免疫原性融合蛋白質，其至少包括：C-末端之第一肽，該第一肽由已缺失B型肝炎病毒(HBV)分離株N-末端之跨膜域的S蛋白質構成；及N-末端之第二肽，該第二肽由來自C型肝炎病毒(HCV)分離株之至少一種外膜蛋白質之跨膜域及胞外域構成。本發明之目標亦為編碼該融合蛋白質之雜合核酸分子，以及包含該雜合核酸分子之載體，包含該融合蛋白質之次病毒顆粒，包含至少該融合蛋白質，或至少該雜合核酸分子，或至少該次病毒顆粒之免疫原性組成物，及產生該融合蛋白質或該雜合核酸分子或該次病毒顆粒之細胞株。
